Abstract
Receptor protein tyrosine phosphatases (RPTPs) are involved in many cellular processes, including the regulation of adhesion, migration and cellular signaling. Many RPTPs are putative tumor suppressors because of the transcriptional and translational changes observed in their expression during tumorigenesis. Recently, RPTPs were shown to be post-translationally regulated during tumorigenesis by proteolysis in a manner similar to proteolysis of the Notch receptor. There is accumulating evidence that proteolysis of RPTPs influence their cellular function and that RPTP fragments may function as oncogenes. By exploiting what is known about RPTP ligand binding domains and crystal structures of ligand-RPTP interfaces, we describe novel molecular diagnostics that have been or can be developed to identify tumor margins and target tumor tissues.
Keywords: Cell-cell interactions, cell-cell adhesion, receptor protein tyrosine phosphatase, RPTPs, cancer, Tumor-derived, Notch receptor, CAMs, Laminin/nidogen, ECD, ADAM
Anti-Cancer Agents in Medicinal Chemistry
Title: Tumor-Derived Extracellular Fragments of Receptor Protein Tyrosine Phosphatases (RPTPs) as Cancer Molecular Diagnostic Tools
Volume: 11 Issue: 1
Author(s): Sonya E.L. Craig and Susann M. Brady-Kalnay
Affiliation:
Keywords: Cell-cell interactions, cell-cell adhesion, receptor protein tyrosine phosphatase, RPTPs, cancer, Tumor-derived, Notch receptor, CAMs, Laminin/nidogen, ECD, ADAM
Abstract: Receptor protein tyrosine phosphatases (RPTPs) are involved in many cellular processes, including the regulation of adhesion, migration and cellular signaling. Many RPTPs are putative tumor suppressors because of the transcriptional and translational changes observed in their expression during tumorigenesis. Recently, RPTPs were shown to be post-translationally regulated during tumorigenesis by proteolysis in a manner similar to proteolysis of the Notch receptor. There is accumulating evidence that proteolysis of RPTPs influence their cellular function and that RPTP fragments may function as oncogenes. By exploiting what is known about RPTP ligand binding domains and crystal structures of ligand-RPTP interfaces, we describe novel molecular diagnostics that have been or can be developed to identify tumor margins and target tumor tissues.
Export Options
About this article
Cite this article as:
E.L. Craig Sonya and M. Brady-Kalnay Susann, Tumor-Derived Extracellular Fragments of Receptor Protein Tyrosine Phosphatases (RPTPs) as Cancer Molecular Diagnostic Tools, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941244
DOI https://dx.doi.org/10.2174/187152011794941244 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Focal Adhesion Kinase in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Fluorescence Imaging of Human Cells with a Novel Conjugate of the Antifungal Nystatin
Medicinal Chemistry Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Self Assembling Polymers as Polymersomes for Drug Delivery
Current Pharmaceutical Design High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Targeting Tumor-Related Immunosuppression for Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenetics and Inflammatory Bowel Disease
Current Pharmacogenomics and Personalized Medicine Natural Products and Cancer Stem Cells
Current Pharmaceutical Design